<DOC>
	<DOCNO>NCT02921828</DOCNO>
	<brief_summary>1 . Planned enrollment period One year ( The plan number patient enrol set 400 patient . ) Since patient prescribe Pomalyst register RevMate® , enrollment use Registration Form surveillance complete time plan number patient enrol reach . During period condition approval remove , system enable retrospectively collect appropriate information base patient data RevMate® , necessary , maintain . 2 . Planned duration surveillance Anticipated 2 year 6 month start date release Pomalyst</brief_summary>
	<brief_title>A Safety Efficacy Pomalyst® Capsules Under Actual Use All Patients Who Are Treated With Pomalyst Dose 1 mg , 2 mg , 3 mg , 4 mg</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<criteria>Among relapsed refractory multiple myeloma patient , patient receive Pomalyst target surveillance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pomalyst</keyword>
	<keyword>Teratogenicity</keyword>
	<keyword>bone marrow suppression</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>infection</keyword>
	<keyword>tumour lysis syndrome</keyword>
	<keyword>somnolence</keyword>
	<keyword>depressed level consciousness</keyword>
	<keyword>confusion</keyword>
	<keyword>fatigue</keyword>
	<keyword>dizziness</keyword>
	<keyword>acute renal failure</keyword>
	<keyword>heart failure</keyword>
	<keyword>arrhythmia</keyword>
	<keyword>interstitial pneumonia</keyword>
	<keyword>hypersensitivity</keyword>
	<keyword>hepatic function disorder</keyword>
	<keyword>jaundice</keyword>
</DOC>